Caliper Completes Divestiture of Product Lines to Biotage

The firm also released pro forma results for its Q1 — reflecting the dispositions of the specialty product lines — showing $2.1 million less in revenues than previously reported, while its cash position increased 45 percent.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.